Compugen Announces First-in-Human Trial for COM503 in Advanced Solid Malignancies

Compugen, a clinical-stage cancer immunotherapy company, announced that a trial in progress of its first-in-human clinical trial assessing anti-IL18BP antibody, COM503, in advanced solid malignancies will be presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer. The poster presentation will be on Friday, November 7, 2025. Compugen is a pioneer in predictive computational target discovery, powered by AI/ML.

Holon, Israel, September 12, 2025 - Compugen Ltd. (Nasdaq: CGEN; TASE: CGEN), a clinical-stage cancer immunotherapy company, has announced that it will present the results of a first-in-human clinical trial assessing the anti-IL18BP antibody, COM503 (GS-0321), at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place between November 7-9, 2025, in National Harbor, Maryland. The poster presentation, titled "A First in Human Clinical Trial to Assess the Anti-IL18BP Antibody, COM503 (GS-0321) in Participants with Advanced Solid Malignancies," will be presented by Dr. Manish Sharma, MD, Co-Director of Clinical Research, START Midwest, Grand Rapids, on Friday, November 7, 2025.

The trial aims to evaluate the safety and efficacy of COM503 in participants with advanced solid malignancies. Compugen, a pioneer in predictive computational target discovery powered by AI/ML, has two proprietary product candidates in Phase 1 development: COM701 and COM902, targeting PVRIG and TIGIT, respectively. Rilvegostomig, a PD-1/TIGIT bispecific antibody derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca. GS-0321, previously known as COM503, is a potential first-in-class, high affinity anti-IL-18 binding protein antibody, currently in Phase 1 development and licensed to Gilead.

Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For more information, please contact Yvonne Naughton, Ph.D., Vice President, Head of Investor Relations and Corporate Communications, at ir@cgen.com or +1 (628) 241-0071.